Synonyms: Avastin® | rhuMAb-VEGF
bevacizumab is an approved drug (FDA (2004), EMA (2005))
Compound class:
Antibody
Comment: Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Biosimilars: Amgen's bevacizumab-awwb (Mvasi®) was the first bevacizumab biosimilar to be FDA approved. This and others are listed in the table below.
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (FDA (2004), EMA (2005)) |
WHO Essential Medicine | WHO Essential Medicines List (EML) (23rd List, 2023). Access PDF version. Click to view more information about the WHO Model Lists of Essential Medicines. |
International Nonproprietary Names ![]() |
|
INN number | INN |
8017 | bevacizumab |
Synonyms ![]() |
Avastin® | rhuMAb-VEGF |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 24 |
Reactome Drug
![]() |
R-ALL-9679458 |
Reactome Reaction
![]() |
R-HSA-9679477 |
Other databases | |
GtoPdb PubChem SID | 178103377 |
PubChem SID | 178103377 |
Search PubMed clinical trials | bevacizumab |
Search PubMed titles | bevacizumab |
Search PubMed titles/abstracts | bevacizumab |
Wikipedia | Bevacizumab |